#Japan #Henderson #VolitionRx #Nu.Q® Vet Cancer Test #Fujifilm Vet Systems

Volition and Fujifilm Bring Automation to Canine Cancer Detection

In an industry-altering announcement, VolitionRx Limited, a prominent epigenetics company, has partnered with Fujifilm Vet Systems Co. Ltd to unveil the world's first automated version of their Nu.Q® Vet Cancer Test. This innovative test aims to revolutionize how veterinarians in Japan diagnose cancer in dogs, providing a more efficient and streamlined approach to canine healthcare.

Advancements in Technology

On March 6, 2026, VolitionRx confirmed the successful completion of validations necessary for implementing full automation in their chemiluminescent immunoassay (ChLIA) for the Nu.Q® Vet Cancer Test. This new system will allow central laboratories to utilize automated processes rather than traditional manual testing methods, thus improving both speed and accuracy in diagnosing canine cancer.

Junichi Makino, the President of Fujifilm Vet Systems, expressed excitement over this milestone: "Being the first globally to implement centralized lab automation for the Nu.Q® Vet Cancer Test signifies a significant leap forward from our existing manual testing methods. The test has seen overwhelming interest since its introduction in July 2024, with over 1,700 veterinary hospitals in Japan eager to adopt this technology. The automation not only enhances efficiency but also ensures a faster turnaround time to meet the increasing demand for reliable cancer screening in pets."

Addressing a Critical Need

Cancer remains the primary cause of death among adult dogs, notorious for claiming the lives of approximately one in four canines. The early detection of cancer can significantly improve treatment outcomes and, consequently, the quality of life for pets. Dr. Jasmine Kway, CEO of Volition Singapore, emphasized the scope of the pet healthcare market in Japan, stating, "With around seven million pet dogs in Japan, the potential for revenue growth in diagnostic testing is tremendous. By targeting the prevalent issue of canine cancer, particularly through our partnership with Fujifilm, we're not only enhancing medical technology but also saving lives."

The Nu.Q® Vet Cancer Test stands out as an accessible and cost-effective tool designed to aid veterinarians in their search for early indicators of cancer in dogs. The significance of diagnosing this disease early cannot be overstated, as timely intervention can lead to improved health outcomes for pet canine patients across the nation.

Synergy between Canines and Humans

The test's successful implementation through the Immunodiagnostic Systems (IDS) i10® automated analyzer platform showcases the seamless integration of Volition's technologies devoted to both human and veterinary diagnostics. This platform is already being utilized for human health assessments via Volition's other products, such as Nu.Q® Cancer, Nu.Q® NETs, and Nu.Q® Discover. The synergy between testing for humans and animals marks a promising advance in medical diagnostics.

The supply agreement allows Fujifilm Vet Systems to not just perform, but also sell the Nu.Q® Vet Cancer Test across their established network of reference laboratories throughout Japan. This broad reach demonstrates a significant push towards enhancing diagnostic capabilities within veterinary practices nationwide.

About Fujifilm Vet Systems

As a subsidiary of Fujifilm Holdings Corporation, Fujifilm Vet Systems is listed on the Tokyo Stock Exchange and specializes in providing comprehensive testing services to veterinary medical facilities. With established connections to approximately 11,000 veterinary establishments across Japan, Fujifilm is positioned as a leading provider of timely diagnostics, facilitating health check-ups and specialized examinations.

Their extensive network and expertise in managing specimen collection and test result reporting are invaluable in the fight against pet diseases.

About VolitionRx

VolitionRx is dedicated to revolutionizing the field of epigenetics by developing and commercializing user-friendly, cost-effective blood tests aimed at diagnosing and monitoring various diseases, including cancers and conditions related to NETosis, such as sepsis. The company's research and development operations are primarily based in Belgium, with additional facilities in the U.S. and London. VolitionRx’s commitment to advancing the science of epigenetics reflects a broader aim of improving health outcomes for both humans and animals.

In conclusion, the partnership between VolitionRx and Fujifilm Vet Systems marks a precedent in veterinary diagnostics with the introduction of the Nu.Q® Vet Cancer Test and its automation, reinforcing the critical importance of early detection in enhancing veterinary care for dogs across Japan.